Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Jakavi Ruxolitinib Myelofibrosis Reimburse with clinical criteria and/or conditions Complete Jun 25, 2012 Jan 14, 2013
Kadcyla Trastuzumab Emtansine Early Breast Cancer (EBC) Reimburse Complete Jul 2, 2019 Jan 22, 2020
Kadcyla Trastuzumab emtansine Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete Mar 15, 2013 Jan 10, 2014
Keytruda Pembrolizumab classical Hodgkin Lymphoma (cHL) Reimburse with clinical criteria and/or conditions Complete Jul 7, 2017 Jan 5, 2018
Keytruda Pembrolizumab For locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete Jul 24, 2017 Mar 2, 2018
Keytruda Pembrolizumab Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete Aug 2, 2019 Apr 2, 2020
Keytruda Pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Complete Dec 13, 2018 Aug 1, 2019
Keytruda Pembrolizumab
Keytruda Pembrolizumab Nonsquamous NSCLC Reimburse with clinical criteria and/or conditions Complete Sep 14, 2018 May 31, 2019
Keytruda Pembrolizumab head and neck squamous cell carcinoma (HNSCC) Reimburse with clinical criteria and/or conditions Complete May 1, 2020 Dec 22, 2020